PNC Financial Services Group Inc. increased its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 6.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 81,438 shares of the exchange traded fund’s stock after acquiring an additional 4,823 shares during the quarter. PNC Financial Services Group Inc.’s holdings in SPDR S&P Biotech ETF were worth $7,334,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of the stock. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in SPDR S&P Biotech ETF by 198.6% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,229,000 shares of the exchange traded fund’s stock valued at $911,825,000 after acquiring an additional 6,138,000 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd bought a new position in SPDR S&P Biotech ETF in the third quarter valued at approximately $141,284,000. Proficio Capital Partners LLC boosted its stake in SPDR S&P Biotech ETF by 16,156.1% in the fourth quarter. Proficio Capital Partners LLC now owns 917,329 shares of the exchange traded fund’s stock valued at $82,615,000 after acquiring an additional 911,686 shares during the last quarter. Mirae Asset Securities USA Inc. boosted its stake in SPDR S&P Biotech ETF by 50.0% in the third quarter. Mirae Asset Securities USA Inc. now owns 900,000 shares of the exchange traded fund’s stock valued at $88,920,000 after acquiring an additional 300,000 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in SPDR S&P Biotech ETF in the fourth quarter valued at approximately $55,529,000.
SPDR S&P Biotech ETF Stock Performance
Shares of XBI stock opened at $86.17 on Wednesday. SPDR S&P Biotech ETF has a 52-week low of $81.14 and a 52-week high of $105.47. The stock has a market cap of $5.68 billion, a PE ratio of 11.47 and a beta of 0.93. The firm’s 50 day moving average price is $90.34 and its two-hundred day moving average price is $95.08.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- How is Compound Interest Calculated?
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Buy P&G Now, Before It Sets A New All-Time High
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.